FDA classifies Vitruvia thyroid recall as highest risk due to superpotency
The FDA has upgraded the recall of Vitruvia Therapeutics 30 mg thyroid tablets to Class I, its highest risk level, because the pills may be superpotent. Approximately 1,900 units distributed nationwide between January and September 2025 are affected. Patients should not stop taking the medication without consulting a doctor, as overactive thyroid symptoms can occur.